British drugmaker GSK and U.S.-based Vir Biotechnology will evaluate a second antibody-based treatment in patients with mild to moderate COVID-19 in an early- to mid-stage trial. The new trial, supported by England’s National Health Service, is expected to begin in the first quarter of 2021 at multiple sites across the UK. Preclinical data suggested the companies’ monoclonal antibody (mAb) has the ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent infection. Source Reuters 12/1/21